Letters to the Editor
Switching to biosimilar infliximab: real world data in patients with severe inflammatory arthritis
C.R. Holroyd1, L. Parker2, S. Bennett3, J. Zarroug4, C. Underhill5, B. Davidson6, R. Armstrong7, N.C. Harvey8, E. Dennison9, C. Cooper10, C.J. Edwards11
- Musculoskeletal Research Unit, University Hospital Southampton NHS Foundation Trust, and MRC Lifecourse Epidemiology Unit, University of Southampton, UK. christopher.holroyd@uhs.nhs.uk
- Musculoskeletal Research Unit, University Hospital Southampton NHS Foundation Trust, UK.
- Musculoskeletal Research Unit, University Hospital Southampton NHS Foundation Trust, UK.
- Musculoskeletal Research Unit, University Hospital Southampton NHS Foundation Trust, UK.
- Musculoskeletal Research Unit, University Hospital Southampton NHS Foundation Trust, UK.
- Musculoskeletal Research Unit, University Hospital Southampton NHS Foundation Trust, UK.
- Musculoskeletal Research Unit, University Hospital Southampton NHS Foundation Trust, UK.
- MRC Lifecourse Epidemiology Unit, University of Southampton, UK.
- MRC Lifecourse Epidemiology Unit, University of Southampton, UK.
- MRC Lifecourse Epidemiology Unit, University of Southampton, UK.
- Musculoskeletal Research Unit, University Hospital Southampton NHS Foundation Trust, and NIHR Wellcome Trust Clinical Research Facility, University Hospital Southampton NHS Foundation Trust, UK.
CER10491
2018 Vol.36, N°1
PI 0171, PF 0172
Letters to the Editor
Free to view
(click on article PDF icon to read the article)
PMID: 29352847 [PubMed]
Received: 08/04/2017
Accepted : 12/06/2017
In Press: 15/01/2018
Published: 06/02/2018